Apnimed, Inc. (NasdaqGS: APMD)
Health Care · Pharmaceuticals · US
$25.63
-19.28% today · +2.5% 1Y
Apnimed, Inc. (NasdaqGS: APMD) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.42B and employs 65 people.
Over the last twelve months the share price has gained 2.5%, trading between 16.12 and 35.29.
APMD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.42B
- Revenue (TTM)
- $120.15M
- P/E
- 3.76
- EPS
- -6.28
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $35.29
- 52-week low
- $16.12
- Avg volume (3M)
- —
- Shares outstanding
- 55.42M
- Employees
- 65
- Next earnings
- —
About Apnimed, Inc.
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
- ISIN
- US03770Y1073
- Founded
- 2017
- Listed since
- Jul 29, 2026
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,248.37 | +0.12% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $271.28 | -0.64% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $151.36 | +0.46% |
| Roche Holding AGSWX: ROP | $368.80B | CHF370.80 | +0.11% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.72 | +0.51% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.02 | +0.18% |
Figures last refreshed Aug 18, 2026.